Tecentriq is administered through Intravenous (IV) infusion, however a new formulation of the drug has recently been developed that can be administered subcutaneously (SC). As opposed to IV infusions, which can require 60-90 minutes of patient time, SC injections can be administered typically less than 10 minutes, thereby reducing the amount of time patients need to spend in medical care facilities. Given the increasing cancer patient statistics rising annually and financial burden facing the Canadian healthcare ecosystem, we planned to investigate operational changes, system impact, Quality of service, economic advancement to its delivery of cancer immunotherapy by shifting its preference from IV formulation to SC formulation. Because of their ease of preparation and administration, Tecentriq SC formulations can be administered to patients at their homes. Providing subcutaneous formulations to patients through EMP nurses at patient homes may allow Horizon Health to optimize healthcare resource use, improve patient access to treatment, and shorten waiting lists. Rural patients, who represent a significant proportion of lung cancer patients in New Brunswick, often face additional barriers regarding time, money and resource associated with travel. The availability of subcutaneous therapies could potentially lead to improvements in Quality of Life for patients and Health Care workers.